Zoetis Inc Class A Common Stoc (ZTS) 51.26 $ZTS
Post# of 273257
Posted On: 09/04/2016 7:03:39 PM
Zoetis Inc Class A Common Stoc (ZTS) 51.26 $ZTS
Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 235.96 (-1.80), ZTS: 51.26 (+0.15), VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), VRX.TO: 37.34 (-0.75)
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 51.26 (+0.15), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38)
Veterinary Vaccines Market is Expected to Rise to US$11,403.6 mn by 2024; Rising Expenditure on Animal Healthcare by Pet Owners and Livestock Farmers to Drive Market Globally, Reports TMR
PR Newswire Europe - Tue Aug 23, 6:31AM CDT
ALBANY, New York, August 23, 2016 /PRNewswire/ --
ZTS: 51.26 (+0.15), MRK: 62.98 (+0.08)
Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and Priceline Group
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:30AM CDT
Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and Priceline Group
BSX: 24.26 (-0.07), ZTS: 51.26 (+0.15), DISCK: 25.08 (+0.13), M: 36.64 (+0.30), PCLN: 1,422.85 (+4.26)
Zoetis Announces Appointment of Glenn David as Executive Vice President and Chief Financial Officer
BusinessWire - Sun Aug 21, 8:13PM CDT
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company's financial management, planning and global operations, effective immediately. As CFO, David will report directly to Chief Executive Officer Juan Ramon Alaix and become part of the Zoetis Executive Team. David will succeed Executive Vice President and Chief Financial Officer Paul Herendeen, who has resigned effective August 18, 2016, to accept the position of CFO at another public company.
ZTS: 51.26 (+0.15)
Top Research Reports for August 19, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 19, 10:44AM CDT
Top Research Reports for August 19, 2016
ZTS: 51.26 (+0.15), AVB: 175.46 (-0.35), LOW: 76.96 (+0.52), TEVA: 51.22 (+0.32), CMCSA: 66.16 (+0.27), VZ: 52.88 (+0.32)
5 Top ROE Stocks to Play in an Aging Bull Market
Supriyo Bose - Zacks Investment Research - Fri Aug 19, 7:05AM CDT
As investors scout for cherry pickings in an aging bull market, they are often on the lookout for "cash cow" stocks that would enable them to milk more cash or profits.
ZTS: 51.26 (+0.15), BSX: 24.26 (-0.07), DISCK: 25.08 (+0.13), M: 36.64 (+0.30), PCLN: 1,422.85 (+4.26)
Zoetis to Participate in the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Aug 11, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016, in New York, N.Y. Juan Ramon Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT.
ZTS: 51.26 (+0.15), MS: 31.89 (-0.02)
Zoetis Acquires Scandinavian Micro Biodevices to Extend Its Pipeline in Diagnostics for Veterinary Use
BusinessWire - Mon Aug 08, 7:00AM CDT
--Adds to diagnostics portfolio with specialty test instruments and cartridges
ZTS: 51.26 (+0.15)
Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:30AM CDT
Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems
BSX: 24.26 (-0.07), ZTS: 51.26 (+0.15), M: 36.64 (+0.30), GIS: 70.94 (+0.83), CTXS: 86.98 (-0.30)
Zoetis (ZTS) Beats on Q2 Earnings & Revenues, Lifts Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:52AM CDT
Zoetis (ZTS) reported better-than-expected second-quarter 2016 earnings of 49 cents per share.
ZTS: 51.26 (+0.15), FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)
Prothena (PRTA) Reports Wider-than-Anticipated Loss in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:45AM CDT
Prothena (PRTA) reported a wider-than-expected loss of $1.18 per share in the second quarter of 2016.
ZTS: 51.26 (+0.15), ANIP: 59.86 (-1.56), PRTA: 52.19 (-0.02)
Zoetis (ZTS) Tops Q2 Earnings, Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:19AM CDT
Zoetis (ZTS) beat both top- and bottom-line estimates in the second quarter of 2016.
ZTS: 51.26 (+0.15)
5 Top ROE Stocks to Buy as Earnings Growth Remains Elusive
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:57AM CDT
A high ROE ensures that the company is reinvesting its cash at a high rate of return.
ZTS: 51.26 (+0.15), BSX: 24.26 (-0.07), M: 36.64 (+0.30), GIS: 70.94 (+0.83), CTXS: 86.98 (-0.30)
Zoetis Reports Second Quarter 2016 Results
BusinessWire - Wed Aug 03, 6:00AM CDT
--Zoetis Reports Adjusted Net Income of $246 Million, or Adjusted Diluted EPS of $0.49, for Second Quarter 2016
ZTS: 51.26 (+0.15)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.26 (+0.15), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CNAT: 1.84 (-0.02), AERI: 19.60 (+0.39), EXEL: 11.54 (+0.19)
Keryx (KERX) Stock Down on Wider Q2 Loss, Supply Issues
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:17AM CDT
Keryx (KERX) announced disruption in the supply of Auryxia tablets along with disappointing second-quarter results.
ZTS: 51.26 (+0.15), INVA: 11.09 (+0.02), ANIP: 59.86 (-1.56), KERX: 4.15 (+0.02)
Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 4:19PM CDT
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 51.26 (+0.15), INVA: 11.09 (+0.02), ANIP: 59.86 (-1.56), SNY: 39.18 (+0.77)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.26 (+0.15), ABT: 42.09 (-0.21), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
Blog Coverage Valeant Pharma Appoints New CEO
ACCESSWIRE - Tue Aug 23, 8:15AM CDT
LONDON, UK / ACCESSWIRE / August 23, 2016 / Active Wall St. blog coverage looks at the headlines from Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and Zoetis Inc. (NYSE: ZTS). Zoetis announced on August 21, 2016, that it had appointed Glenn David as its Executive Vice President and Chief Financial Officer (CFO). The announcement came in the wake of the resignation of Executive Vice President and CFO Paul S. Herendeen on August 18, 2016. On August, 22, 2016, Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced the appointment of Paul S. Herendeen to take on the role of CFO from Robert L. Rosiello. Register with us now for your free membership and blog access at: http://www.activewallst.com/register/.
AGN: 235.96 (-1.80), ZTS: 51.26 (+0.15), VRX: 28.76 (-0.36), TROW: 69.27 (+0.52), VRX.TO: 37.34 (-0.75)
Eli Lilly, AstraZeneca Alzheimer's Drug Gets FDA Fast Track
Arpita Dutt - Zacks Investment Research - Tue Aug 23, 7:59AM CDT
Eli Lilly (LLY) and AstraZeneca's (AZN) Alzheimer's disease treatment is currently in phase III studies.
ZTS: 51.26 (+0.15), AZN: 33.31 (+0.71), LLY: 76.85 (-0.38)
Veterinary Vaccines Market is Expected to Rise to US$11,403.6 mn by 2024; Rising Expenditure on Animal Healthcare by Pet Owners and Livestock Farmers to Drive Market Globally, Reports TMR
PR Newswire Europe - Tue Aug 23, 6:31AM CDT
ALBANY, New York, August 23, 2016 /PRNewswire/ --
ZTS: 51.26 (+0.15), MRK: 62.98 (+0.08)
Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and Priceline Group
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 8:30AM CDT
Zacks.com featured highlights: Macy's, Discovery Communications, Zoetis, Boston Scientific and Priceline Group
BSX: 24.26 (-0.07), ZTS: 51.26 (+0.15), DISCK: 25.08 (+0.13), M: 36.64 (+0.30), PCLN: 1,422.85 (+4.26)
Zoetis Announces Appointment of Glenn David as Executive Vice President and Chief Financial Officer
BusinessWire - Sun Aug 21, 8:13PM CDT
Zoetis Inc. (NYSE:ZTS) today announced that Glenn David, Senior Vice President of Finance Operations, has been named Executive Vice President and Chief Financial Officer (CFO), and will assume responsibility for the oversight of the company's financial management, planning and global operations, effective immediately. As CFO, David will report directly to Chief Executive Officer Juan Ramon Alaix and become part of the Zoetis Executive Team. David will succeed Executive Vice President and Chief Financial Officer Paul Herendeen, who has resigned effective August 18, 2016, to accept the position of CFO at another public company.
ZTS: 51.26 (+0.15)
Top Research Reports for August 19, 2016
Sheraz Mian - Zacks Investment Research - Fri Aug 19, 10:44AM CDT
Top Research Reports for August 19, 2016
ZTS: 51.26 (+0.15), AVB: 175.46 (-0.35), LOW: 76.96 (+0.52), TEVA: 51.22 (+0.32), CMCSA: 66.16 (+0.27), VZ: 52.88 (+0.32)
5 Top ROE Stocks to Play in an Aging Bull Market
Supriyo Bose - Zacks Investment Research - Fri Aug 19, 7:05AM CDT
As investors scout for cherry pickings in an aging bull market, they are often on the lookout for "cash cow" stocks that would enable them to milk more cash or profits.
ZTS: 51.26 (+0.15), BSX: 24.26 (-0.07), DISCK: 25.08 (+0.13), M: 36.64 (+0.30), PCLN: 1,422.85 (+4.26)
Zoetis to Participate in the Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Aug 11, 7:30AM CDT
Zoetis Inc.(NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 14, 2016, in New York, N.Y. Juan Ramon Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. He is scheduled to present at 10:30 a.m. EDT.
ZTS: 51.26 (+0.15), MS: 31.89 (-0.02)
Zoetis Acquires Scandinavian Micro Biodevices to Extend Its Pipeline in Diagnostics for Veterinary Use
BusinessWire - Mon Aug 08, 7:00AM CDT
--Adds to diagnostics portfolio with specialty test instruments and cartridges
ZTS: 51.26 (+0.15)
Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems
Zacks Equity Research - Zacks Investment Research - Thu Aug 04, 8:30AM CDT
Zacks.com featured highlights: Macy's, General Mills, Zoetis, Boston Scientific and Citrix Systems
BSX: 24.26 (-0.07), ZTS: 51.26 (+0.15), M: 36.64 (+0.30), GIS: 70.94 (+0.83), CTXS: 86.98 (-0.30)
Zoetis (ZTS) Beats on Q2 Earnings & Revenues, Lifts Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:52AM CDT
Zoetis (ZTS) reported better-than-expected second-quarter 2016 earnings of 49 cents per share.
ZTS: 51.26 (+0.15), FCSC: 0.89 (-0.01), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)
Prothena (PRTA) Reports Wider-than-Anticipated Loss in Q2
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:45AM CDT
Prothena (PRTA) reported a wider-than-expected loss of $1.18 per share in the second quarter of 2016.
ZTS: 51.26 (+0.15), ANIP: 59.86 (-1.56), PRTA: 52.19 (-0.02)
Zoetis (ZTS) Tops Q2 Earnings, Revenue Estimates
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 8:19AM CDT
Zoetis (ZTS) beat both top- and bottom-line estimates in the second quarter of 2016.
ZTS: 51.26 (+0.15)
5 Top ROE Stocks to Buy as Earnings Growth Remains Elusive
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 7:57AM CDT
A high ROE ensures that the company is reinvesting its cash at a high rate of return.
ZTS: 51.26 (+0.15), BSX: 24.26 (-0.07), M: 36.64 (+0.30), GIS: 70.94 (+0.83), CTXS: 86.98 (-0.30)
Zoetis Reports Second Quarter 2016 Results
BusinessWire - Wed Aug 03, 6:00AM CDT
--Zoetis Reports Adjusted Net Income of $246 Million, or Adjusted Diluted EPS of $0.49, for Second Quarter 2016
ZTS: 51.26 (+0.15)
Drug Stocks to Watch for Earnings on Aug 3: ZTS, EXEL & More
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 9:30AM CDT
Can drug stocks Zoetis, Conatus and others pull a surprise when they report their Q2 results on Aug 3?
ZTS: 51.26 (+0.15), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), GERN: 2.75 (+0.02), CNAT: 1.84 (-0.02), AERI: 19.60 (+0.39), EXEL: 11.54 (+0.19)
Keryx (KERX) Stock Down on Wider Q2 Loss, Supply Issues
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 8:17AM CDT
Keryx (KERX) announced disruption in the supply of Auryxia tablets along with disappointing second-quarter results.
ZTS: 51.26 (+0.15), INVA: 11.09 (+0.02), ANIP: 59.86 (-1.56), KERX: 4.15 (+0.02)
Sanofi (SNY) Posts In-Line Q2 Earnings, Revenues Down Y/Y
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 4:19PM CDT
Sanofi (SNY) reported second-quarter 2016 business earnings of 74 cents per American Depositary Share, in line with the Zacks Consensus Estimate.
ZTS: 51.26 (+0.15), INVA: 11.09 (+0.02), ANIP: 59.86 (-1.56), SNY: 39.18 (+0.77)
Zoetis (ZTS): Stock to Beat Earnings Estimates in Q2 Again
Zacks Equity Research - Zacks Investment Research - Mon Aug 01, 11:01AM CDT
Zoetis (ZTS), which is set to report second-quarter 2016 results on Aug 3, had delivered a positive earnings surprise of 17.07% last quarter.
ZTS: 51.26 (+0.15), ABT: 42.09 (-0.21), ICPT: 150.74 (+3.92), EXEL: 11.54 (+0.19)
(0)
(0)Scroll down for more posts ▼